BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schechter MS. Nongenetic influences on cystic fibrosis outcomes. Curr Opin Pulm Med 2011;17:448-54. [PMID: 21897254 DOI: 10.1097/MCP.0b013e32834ba899] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Raraigh KS, Paul KC, Goralski JL, Worthington EN, Faino AV, Sciortino S, Wang Y, Aksit MA, Ling H, Osorio DL, Onchiri FM, Patel SU, Merlo CA, Montemayor K, Gibson RL, West NE, Thakerar A, Bridges RJ, Sheppard DN, Sharma N, Cutting GR. CFTR bearing variant p.Phe312del exhibits function inconsistent with phenotype and negligible response to ivacaftor. JCI Insight 2022;7:e148841. [PMID: 35315358 DOI: 10.1172/jci.insight.148841] [Reference Citation Analysis]
2 Skopelja S, Hamilton BJ, Jones JD, Yang ML, Mamula M, Ashare A, Gifford AH, Rigby WF. The role for neutrophil extracellular traps in cystic fibrosis autoimmunity. JCI Insight 2016;1:e88912. [PMID: 27777975 DOI: 10.1172/jci.insight.88912] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 7.5] [Reference Citation Analysis]
3 Ong T, Schechter M, Yang J, Peng L, Emerson J, Gibson RL, Morgan W, Rosenfeld M; EPIC Study Group. Socioeconomic Status, Smoke Exposure, and Health Outcomes in Young Children With Cystic Fibrosis. Pediatrics 2017;139:e20162730. [PMID: 28093464 DOI: 10.1542/peds.2016-2730] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
4 Taylor-Robinson DC, Smyth RL, Diggle PJ, Whitehead M. The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study. Lancet Respir Med 2013;1:121-8. [PMID: 24429092 DOI: 10.1016/S2213-2600(13)70002-X] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 5.9] [Reference Citation Analysis]
5 Currie G, Tai A, Snelling T, Schultz A. Variation in treatment preferences of pulmonary exacerbations among Australian and New Zealand cystic fibrosis physicians. BMJ Open Respir Res 2021;8:e000956. [PMID: 34266854 DOI: 10.1136/bmjresp-2021-000956] [Reference Citation Analysis]
6 Farhat SCL, Almeida MB, Silva-Filho LVRF, Farhat J, Rodrigues JC, Braga ALF. Ozone is associated with an increased risk of respiratory exacerbations in patients with cystic fibrosis. Chest 2013;144:1186-92. [PMID: 23493973 DOI: 10.1378/chest.12-2414] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
7 Britton LJ, Oates GR, Oster RA, Self ST, Troxler RB, Hoover WC, Gutierrez HH, Harris WT. Risk stratification model to detect early pulmonary disease in infants with cystic fibrosis diagnosed by newborn screening. Pediatr Pulmonol 2016;51:1168-76. [PMID: 27556254 DOI: 10.1002/ppul.23536] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Terlizzi V, Lucarelli M, Salvatore D, Angioni A, Bisogno A, Braggion C, Buzzetti R, Carnovale V, Casciaro R, Castaldo G, Cirilli N, Collura M, Colombo C, Di Lullo AM, Elce A, Lucidi V, Madarena E, Padoan R, Quattrucci S, Raia V, Seia M, Termini L, Zarrilli F. Clinical expression of cystic fibrosis in a large cohort of Italian siblings. BMC Pulm Med. 2018;18:196. [PMID: 30577776 DOI: 10.1186/s12890-018-0766-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
9 Stonebraker JR, Ooi CY, Pace RG, Corvol H, Knowles MR, Durie PR, Ling SC. Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis. Clin Gastroenterol Hepatol 2016;14:1207-1215.e3. [PMID: 27062904 DOI: 10.1016/j.cgh.2016.03.041] [Cited by in Crossref: 71] [Cited by in F6Publishing: 55] [Article Influence: 11.8] [Reference Citation Analysis]
10 Oates GR, Baker E, Rowe SM, Gutierrez HH, Schechter MS, Morgan W, Harris WT. Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis. J Cyst Fibros 2020;19:783-90. [PMID: 32081643 DOI: 10.1016/j.jcf.2020.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
11 Oates GR, Schechter MS. Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies. Expert Rev Respir Med 2022;:1-14. [PMID: 35705523 DOI: 10.1080/17476348.2022.2090928] [Reference Citation Analysis]
12 McGarry ME, Neuhaus JM, Nielson DW, Ly NP. Regional variations in longitudinal pulmonary function: A comparison of Hispanic and non-Hispanic subjects with cystic fibrosis in the United States. Pediatr Pulmonol 2019;54:1382-90. [PMID: 31144477 DOI: 10.1002/ppul.24377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
13 Oates GR, Stepanikova I, Gamble S, Gutierrez HH, Harris WT. Adherence to airway clearance therapy in pediatric cystic fibrosis: Socioeconomic factors and respiratory outcomes. Pediatr Pulmonol 2015;50:1244-52. [PMID: 26436321 DOI: 10.1002/ppul.23317] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
14 Bradley GM, Blackman SM, Watson CP, Doshi VK, Cutting GR. Genetic modifiers of nutritional status in cystic fibrosis. Am J Clin Nutr 2012;96:1299-308. [PMID: 23134884 DOI: 10.3945/ajcn.112.043406] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
15 LaRusch J, Jung J, General IJ, Lewis MD, Park HW, Brand RE, Gelrud A, Anderson MA, Banks PA, Conwell D, Lawrence C, Romagnuolo J, Baillie J, Alkaade S, Cote G, Gardner TB, Amann ST, Slivka A, Sandhu B, Aloe A, Kienholz ML, Yadav D, Barmada MM, Bahar I, Lee MG, Whitcomb DC; North American Pancreatitis Study Group. Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis. PLoS Genet. 2014;10:e1004376. [PMID: 25033378 DOI: 10.1371/journal.pgen.1004376] [Cited by in Crossref: 105] [Cited by in F6Publishing: 92] [Article Influence: 13.1] [Reference Citation Analysis]
16 Lanzkron S, Sawicki GS, Hassell KL, Konstan MW, Liem RI, McColley SA. Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. J Clin Transl Sci 2018;2:334-42. [PMID: 30828476 DOI: 10.1017/cts.2018.338] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
17 Muhlebach MS, Jiang X, Kosorok MR, Klein EY, Saiman L. Longitudinal changes and regional variation of incident infection rates at cystic fibrosis centers, United States 2010-2016. J Cyst Fibros 2021:S1569-1993(21)01350-3. [PMID: 34456157 DOI: 10.1016/j.jcf.2021.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]